REGORAFENIB
| Brand name | STIVARGA |
|---|---|
| Active ingredient | REGORAFENIB |
| Strength | 40MG |
| Dosage form | TABLET |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | September 2012 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 9957232 | July 2032 | substance |
| 9458107 | April 2031 | product |
| 8637553 | February 2031 | substance, product |
| 8680124 | June 2030 | use U-1506 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.